First Time Loading...

Taisho Pharmaceutical Holdings Co Ltd
TSE:4581

Watchlist Manager
Taisho Pharmaceutical Holdings Co Ltd Logo
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
Watchlist
Price: 999 999.9999 JPY Market Closed
Updated: May 14, 2024
Taisho Pharmaceutical Holdings Co Ltd
/
Income Statement
/
Income from Continuing Operations

Taisho Pharmaceutical Holdings Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Taisho Pharmaceutical Holdings Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
Income from Continuing Operations
¥10.9B
CAGR 3-Years
-17%
CAGR 5-Years
-28%
CAGR 10-Years
-11%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
¥178.3B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
¥186.6B
CAGR 3-Years
38%
CAGR 5-Years
23%
CAGR 10-Years
6%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
¥141.7B
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
¥325.5B
CAGR 3-Years
15%
CAGR 5-Years
28%
CAGR 10-Years
20%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
¥37.3B
CAGR 3-Years
-35%
CAGR 5-Years
-29%
CAGR 10-Years
-9%

See Also

What is Taisho Pharmaceutical Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
10.9B JPY

Based on the financial report for Dec 31, 2023, Taisho Pharmaceutical Holdings Co Ltd's Income from Continuing Operations amounts to 10.9B JPY.

What is Taisho Pharmaceutical Holdings Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-11%

Over the last year, the Income from Continuing Operations growth was -60%. The average annual Income from Continuing Operations growth rates for Taisho Pharmaceutical Holdings Co Ltd have been -17% over the past three years , -28% over the past five years , and -11% over the past ten years .

ALPHA SPREAD
Join more than 137,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.